•Universitat Pompeu Fabra (UPF) is a young public university in Barcelona. Committed from the start to excellence, it ranks 17th worldwide among under-50 universities, 1st in Spain, 60th in Europe and 140th worldwide (THE ranking 2018). UPF Department of Experimental and Health Sciences (DCEXS) is located in the Barcelona Biomedical Research Park (PRBB), one of the largest research hubs in Europe.

•The research group of proteomics and protein chemistry at UPF leaded by Prof. David Andreu has an international recognition in various aspects of peptide research, particularly on the development of vaccines, peptide-based drugs and synthetic methods.

•In the ElectroMed project, David Andreu together with his postdoc collaborator Eduard Figueras will develop and optimize a chemistry protocol for the electrochemically driven synthesis of peptides in microfluidic devices.


•David Andreu PhD, (WP leader): trained as a peptide chemist with Nobel laureate Bruce Merrifield at Rockefeller University (1982-85), served as associate professor at the University of Barcelona (1986-2001) and in 2002 was appointed professor of Chemistry at Pompeu Fabra University, Barcelona. He is the current president of the European Peptide Society and the editor-in-chief of Drugs of the Future.

•Eduard Figueras, PhD, obtained his doctoral degree at Bielefeld University (2019) working on peptide-drug conjugates for targeted delivery in tumor therapy within the European Training Network MAGICBULLET. After a short stay in the Regulatory Affairs department of Medichem, he then joined the research group of Prof. David Andreu as postdoctoral researcher in the ElectroMed project.  

Share this page